Based on the kinome reprogramming triggered by T-RECS ASO and its significant impact on AKT1 and PIM1 activities, it is possible that jointly targeting MEK and T-RECS directly inhibits both the MAPK and AKT pathways, which are the two main drivers of therapeutic resistance and melanoma progression [2, 23]. The gene discussed is AKT1; the disease is melanoma.